Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in pediatric plaque psoriasis
NCT04175613Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2019
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Amgen. Primary endpoints: Adverse Events up to 4 years, Columbia-Suicide Severity Rating Scale and 4 more. Started Dec 2019; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04175613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175613.